Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

doi:10.1016/S0140-6736(20)32078-X

Comment

. 2020 Oct 24;396(10259):1310-1311.

doi: 10.1016/S0140-6736(20)32078-X. Epub 2020 Oct 5.

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Bin Cao¹, Frederick G Hayden²

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Department of Respiratory Medicine, Capital Medical University, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China. Electronic address: caobin_ben@163.com.
² Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.

PMID: 33031761
PMCID: PMC7535876
DOI: 10.1016/S0140-6736(20)32078-X

Comment

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Bin Cao et al. Lancet. 2020.

. 2020 Oct 24;396(10259):1310-1311.

doi: 10.1016/S0140-6736(20)32078-X. Epub 2020 Oct 5.

Authors

Bin Cao¹, Frederick G Hayden²

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Department of Respiratory Medicine, Capital Medical University, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China. Electronic address: caobin_ben@163.com.
² Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.

PMID: 33031761
PMCID: PMC7535876
DOI: 10.1016/S0140-6736(20)32078-X

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Comment on

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5. Lancet. 2020. PMID: 33031764 Free PMC article. Clinical Trial.

Cited by

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.
Ferreras C, Pascual-Miguel B, Mestre-Durán C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, De Paz R, Marcos A, Vicario JL, Balas A, García-Sánchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Pérez-Martínez A. Ferreras C, et al. Front Cell Dev Biol. 2021 Feb 25;9:620730. doi: 10.3389/fcell.2021.620730. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33718360 Free PMC article.
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis.
Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Deng J, et al. Infection. 2023 Feb;51(1):21-35. doi: 10.1007/s15010-022-01825-8. Epub 2022 Apr 19. Infection. 2023. PMID: 35438413 Free PMC article.
Traditional Chinese medicine in COVID-19.
Lyu M, Fan G, Xiao G, Wang T, Xu D, Gao J, Ge S, Li Q, Ma Y, Zhang H, Wang J, Cui Y, Zhang J, Zhu Y, Zhang B. Lyu M, et al. Acta Pharm Sin B. 2021 Nov;11(11):3337-3363. doi: 10.1016/j.apsb.2021.09.008. Epub 2021 Sep 20. Acta Pharm Sin B. 2021. PMID: 34567957 Free PMC article. Review.
Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.
Batalha PN, Forezi LSM, Lima CGS, Pauli FP, Boechat FCS, de Souza MCBV, Cunha AC, Ferreira VF, da Silva FC. Batalha PN, et al. Bioorg Chem. 2021 Jan;106:104488. doi: 10.1016/j.bioorg.2020.104488. Epub 2020 Nov 19. Bioorg Chem. 2021. PMID: 33261844 Free PMC article. Review.
Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.
Urakov A, Urakova N, Reshetnikov A, Shklyaev A, Nikolenko V, Osipov A, Klyachko N, Sorokina Y, Muhutdinov N, Okovityi S, Shabanov P. Urakov A, et al. Curr Top Med Chem. 2024;24(25):2191-2210. doi: 10.2174/0115680266322046240819053909. Curr Top Med Chem. 2024. PMID: 39253918

See all "Cited by" articles

References

1. RECOVERY Collaborative Group Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32013-4. published online Oct 5. - DOI - PMC - PubMed
1. Cao B, Wang Y, Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. - PMC - PubMed
1. WHO WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 4, 2020. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxy...
1. Siemieniuk RA, Bartoszko JJ, Ge L. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370 - PMC - PubMed
1. Williamson BN, Feldmann F, Schwarz B. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585:273–276. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

WT_/Wellcome Trust/United Kingdom

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] RECOVERY Collaborative Group Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32013-4. published online Oct 5. - DOI - PMC - PubMed

[2] RECOVERY Collaborative Group Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32013-4. published online Oct 5. - DOI - PMC - PubMed

[3] Cao B, Wang Y, Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. - PMC - PubMed

[4] Cao B, Wang Y, Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. - PMC - PubMed

[5] WHO WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 4, 2020. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxy...

[6] WHO WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 4, 2020. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxy...

[7] Siemieniuk RA, Bartoszko JJ, Ge L. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370 - PMC - PubMed

[8] Siemieniuk RA, Bartoszko JJ, Ge L. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370 - PMC - PubMed

[9] Williamson BN, Feldmann F, Schwarz B. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585:273–276. - PMC - PubMed

[10] Williamson BN, Feldmann F, Schwarz B. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585:273–276. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Affiliations

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Authors

Affiliations

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical